```
 * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:18:31 ON 26 MAY 2005

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10713722.str
```




```
chain nodes :
1  2  3  4  5  10  11  12  13  14  15  16  17
chain bonds :
1-2  2-3  3-4  4-5  5-10  10-11  11-12  11-13  12-14  12-16  13-15  13-17
exact/norm bonds :
1-2  2-3  3-4  4-5  5-10  12-14  12-16  13-15  13-17
exact bonds :
10-11  11-12  11-13


G1:O,S,N

Match level :
1:Atom  2:CLASS  3:CLASS  4:CLASS  5:Atom  10:CLASS  11:CLASS  12:CLASS  13:CLASS
14:CLASS  15:CLASS  16:CLASS  17:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 O,S,N
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
FULL SEARCH INITIATED 14:18:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 780176 TO ITERATE

 44.8% PROCESSED  349280 ITERATIONS                              31 ANSWERS

 51.3% PROCESSED  400000 ITERATIONS                              31 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.36

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       780176 TO   780176
PROJECTED ANSWERS:              37 TO       83

L3            31 SEA SSS FUL L1

=> file ca

=> s l3
L4             5 L3

=> d ibib abs hitstr 1-5
```

L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 142:373683 CA
TITLE: Preparation of 1,3-diketone compounds useful for treatment of diabetes, obesity and hyperlipidemia
INVENTOR(S): Yang, Yushe; Tang, Lei; Ji, Ruyun; Chen, Kaixian; Sun, Piaoyang
PATENT ASSIGNEE(S): Shanghai Institute of Pharmacy, Chinese Academy of Sciences, Peop. Rep. China; Hengrui Medicine Co., Ltd., Jiangsu
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 25 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1478770	A	20040303	CN 2002-136715	20020829
PRIORITY APPLN. INFO.:			CN 2002-136715	20020829

GI



I



II

AB Title compds. I [wherein R1, R2 = alkyl, alkoxy, alkylamino, heterocyclic amino, hydrazino, etc.; R3 = -CH2OH, -CO2CH3, - CH2OCHO, -CH2O2CH3 or H; R4 = certain (un)substituted indolyl or pyridinylamino; n = 1-4, with some limitations) were prepared For instance, condensation of 4-[2-(N-methyl-2-pyridinylamino)ethoxy]benzaldehyde with di-Me malonate in toluene followed by Pd/C-catalyzed hydrogenation of the resultant alkene with H2 in methanol-dioxane gave II in 59.1% yield (for two steps). Some I showed strong insulin-sensitizing activity. Therefore, I are useful in the treatment of type II diabetes, obesity and hyperlipidemia.

IT **610280-91-6P 610280-92-7P 610280-94-9P**
610280-96-1P 610280-97-2P 610280-99-4P
610281-01-1P 610281-03-3P 610281-05-5P
610281-07-7P 610281-08-8P

L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 1,3-diketone compds. with insulin-sensitizing activity)

RN 610280-91-6 CA
CN Propanediamide, N,N'-dihydroxy-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 610280-92-7 CA
CN Propanedioic acid, [[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, dihydrazide (9CI) (CA INDEX NAME)



RN 610280-94-9 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(2-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 610280-96-1 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(3-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 610280-97-2 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(4-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 610280-99-4 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(2-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610281-01-1 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(3-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610281-03-3 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(4-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 610281-05-5 CA
CN Propanediamide, N,N'-dimethyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 610281-07-7 CA
CN Propanediamide, 2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-N,N'-diphenyl- (9CI) (CA INDEX NAME)



RN 610281-08-8 CA
CN Propanediamide, N,N'-dicyclopropyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 2 OF 5 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 142:177008 CA

TITLE: Mono- and Bivalent Ligands Bearing Mannose 6-Phosphate (M6P) Surrogates: Targeting the M6P/Insulin-Like Growth Factor II Receptor

AUTHOR(S): Berkowitz, David B.; Maiti, Gourhari; Charette, Bradley D.; Dreis, Christine D.; MacDonald, Richard G.

CORPORATE SOURCE: Department of Chemistry, University of Nebraska, Lincoln, NE, 68588-0304, USA

SOURCE: Organic Letters (2004), 6(26), 4921-4924
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mannose 6-phosphate mimics locked into the α-configuration and bearing hydrolase-resistant phosphate surrogates were synthesized and evaluated for binding affinity to the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R). Affinity increases as the phosphate surrogate is varied in the order malonyl ether < malonate < phosphonate. An alkene cross-metathesis approach to sought-after bivalent M6P-bearing ligands is also described. These compds. were designed to map onto biantennary sectors of high-mannose-type oligosaccharides carried by glycoprotein M6P/IGF2R ligands. 66472069H.

IT **833489-25-1P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(mono and bivalent ligands bearing mannose phosphate m surrogates targeting mp insulinlike growth factor ii receptor)

RN 833489-25-1 CA

CN α-D-manno-Octopyranosiduronic acid, 1,4-butanediyl bis[7-carboxy-6,7-dideoxy-, tetraammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●4 NH_3

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 141:173856 CA

TITLE: Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARα selective activators

AUTHOR(S): Li, Zhibin; Liao, Chenzhong; Ko, Ben C. B.; Shan, Song; Tong, Edith H. Y.; Yin, Zihui; Pan, Desi; Wong, Vincent K. W.; Shi, Leming; Ning, Zhi-Qiang; Hu, Weiming; Zhou, Jiaju; Chung, Stephen S. M.; Lu, Xian-Ping

CORPORATE SOURCE: Chipscreen Biosciences, Ltd, Research Institute of Tsinghua University, Shenzhen, 518057, Peop. Rep. China

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3507-3511
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:173856

GI



I



II

AB Lipid accumulation in nonadipose tissues is increasingly linked to the development of type 2 diabetes in obese individuals. The design, synthesis, and evaluation of a series of novel PPARα selective activators containing 1,3-dicarbonyl moieties. Structure-activity relationship studies led to the identification of PPARα selective activators with stronger potency and efficacy to activate PPARα over PPARγ and PPARδ. Expts. in vivo showed that compds. I, and II (R1, R2 = OMe; R1 = OH, R2 = NH2) had blood glucose lowering effect in diabetic db/db mouse model after two weeks oral dosing. The data strongly support further testing of these lead compds. in other relevant disease animal models to evaluate their potential therapeutic benefits.

IT **701294-91-9P 701294-92-0P 701294-93-1P**
701294-94-2P 701294-97-5P 701979-39-7P
701979-41-1P 701979-45-5P 701979-46-6P
736171-91-8P 736171-93-0P 736171-94-1P
736171-95-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compds. as PPARα selective activators for the treatment of diabetes)

L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

RN 701294-91-9 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 701294-92-0 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 701294-93-1 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 701294-94-2 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 701294-97-5 CA
CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 701979-39-7 CA
CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 701979-41-1 CA
CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 701979-45-5 CA
CN Propanedioic acid, [[4-[2-(2-naphthalenyloxy)ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 736171-95-2 CA
CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(1,2,3,4-tetrahydro-6-quinolinyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 701979-46-6 CA
CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-(2-naphthalenyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 736171-91-8 CA
CN Propanedioic acid, [[4-[2-(2-naphthalenyloxy)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 736171-93-0 CA
CN Propanedioic acid, [[4-[2-[(1,2,3,4-tetrahydro-6-quinolinyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 736171-94-1 CA
CN Propanedioic acid, [[4-[2-[(1,2,3,4-tetrahydro-6-quinolinyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 141:38535 CA
TITLE: Preparation of noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
INVENTOR(S): Lu, Xian-Ping; Li, Zhibin; Liao, Chenzhong; Shi, Leming; Liu, Zhende; Ning, Zhiqiang; Shan, Song; Deng, Tuo; Ma, Baoshun
PATENT ASSIGNEE(S): Shenzhen Chipscreen Biosciences Ltd., Peop. Rep. China
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048338	A1	20040610	WO 2003-IB5294	20031119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004138211	A1	20040715	US 2003-713722	20031114
PRIORITY APPLN. INFO.:			US 2002-429294P	P 20021126
			US 2003-713722	A 20031114

OTHER SOURCE(S): MARPAT 141:38535
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compds. I [ring A (fused to ring B) = (un)substituted, (un)saturated 5- or 6-membered ring optionally containing 1 or more of O, S, N (optionally substituted with one or more halogen, OH, NO2, CN, alkyl, alkenyl, alkenynyl, aralkyl, heteroarylalkyl, aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, hydroxyalkyl, thioalkyl, heterocyclyl, alkoxy, aryl, aryloxy, aralkoxy, heteroaryl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, NH2, alkylamino, arylamino, aralkylamino); ring B (fused to ring A) = (un)substituted , (un)saturated 5- or 6-membered ring optionally containing 1 or more of O, S, N (optionally substituted as in A); R1, R2, R3 = H, alkyl, alkenyl, alkynyl, aralkyl, heteroarylalkyl, aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, hydroxyalkyl, thioalkyl, heterocyclyl, OH, halogen, alkoxy, aryl, aryloxy, aralkoxy, heteroaryl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, NH2, alkylamino, arylamino, aralkylamino; R4, R5 = H, alkyl, alkenyl, alkenynyl, aralkyl, heteroarylalkyl, heterocycle, aryl, heteroaryl; X, Y = O, S, NR6; R6 = H, C1-3-alkyl; Q, Z = O, S, NR7; R7 = H, alkyl, aryl, arylalkyl; Ar = (un)substituted arylene, heteroarylene, divalent heterocycle (optionally substituted with halogen, C1-6-alkyl, NH2, OH, C1-6-alkoxy, aryl)); n = 1

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

-6], their stereoisomers, enantiomers, diastereomers, hydrates or pharmaceutically acceptable salts. A process for the prepn. of I is characterized b: (a) reaction of bicyclic compd. II with 4-(BrCH2CH2O)C6H4CHO in the presence of KOH; (b) Knoevenagel reaction of benzaldehyde III with CH2(CO2Me)2 in the presence of catalytic piperidinium acetate; (c) catalytic hydrogenation of benzylidene III with H2 in the presence of Pd/C to give benzylmalontes V; (d) the other 1,3-dicarbonyl compds. I are prepd. via hydrolysis or other conventional reactions. Thus, malonamide I [AB = 6-quinolinyl, X = O, n = 2, Y = O, Ar = 1,4-phenylene, R1-R3 = H, ZR4 = OH, QR5 = NH2 (VI)] was prepd. from 6-quinolinol via etherification with 4-(BrCH2CH2O)C6H4CHO in EtOH contg. KOH, Knoevenagel condensation with CH2(CO2Me)2 in PhMe contg. catalytic piperidinium acetate, catalytic hydrogenation in EtOH in the presence of Pd/C, partial hydrolysis with aq. NaOH in THF/MeOH, amidation (SOCl2 in C6H6 then 28% ammonia soln.) and sapon. with aq. NaOH in THF/MeOH. These compds., as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPARγ and RXR/PPARα heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and assocd. metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders. Agonist activity of VI (AB = quinoline, X = 6-O, n = 2, Y = O, Ar = 1,4-phenylene, R1-R3 = H, ZR4 = OH, QR5 = NH2) vs. RXR/PPARγ and RXR/PPARα heterodimers studied (see graphs).

IT **701294-91-9P 701979-39-7P 701979-45-5P 701979-48-8P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and amidation of; preparation of noncyclic 1,3-dicarbonyl compds. as dual PPAR agonists with antihyperglycemic and antihyperlipidemic activity)

RN 701294-91-9 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 701979-39-7 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 701294-97-5 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 701295-01-4 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-(2-naphthalenyloxy)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 701295-04-7 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(1,2,3,4-tetrahydro-7-quinolinyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **701294-92-0P 701294-94-2P 701294-98-6P 701979-41-1P 701979-46-6P 701979-49-9P**

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 701979-45-5 CA

CN Propanedioic acid, [[4-[2-(2-naphthalenyloxy)ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 701979-48-8 CA

CN Propanedioic acid, [[4-[2-[(1,2,3,4-tetrahydro-7-quinolinyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



IT **701294-93-1P 701294-97-5P 701295-01-4P 701295-04-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and saponification of; preparation of noncyclic 1,3-dicarbonyl compds. as dual PPAR agonists with antihyperglycemic and antihyperlipidemic activity)

RN 701294-93-1 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of noncyclic 1,3-dicarbonyl compds. as dual PPAR agonists with antihyperglycemic and antihyperlipidemic activity)

RN 701294-92-0 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 701294-94-2 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 701294-98-6 CA

CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 701979-41-1 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 701979-46-6 CA

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)
CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-(2-naphthalenyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 701979-49-9 CA
CN Benzenepropanoic acid, α-(aminocarbonyl)-4-[2-[(1,2,3,4-tetrahydro-7-quinolinyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:307663 CA
TITLE: Synthesis and insulin-sensitizing activity of a series of 2-benzyl-1,3-dicarbonyl derivatives
AUTHOR(S): Tang, Lei; Leng, Ying; Wang, Huo-Quan; Feng, Ying; Yang, Yu-She; Ji, Ru-Yun
CORPORATE SOURCE: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China
SOURCE: Chinese Journal of Chemistry (2003), 21(4), 365-368 CODEN: CJOCEV; ISSN: 1001-604X
PUBLISHER: Science Press
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:307663
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of 2-benzyl-1,3-dicarbonyl derivs., e.g. I, was synthesized. Their insulin-sensitizing activity was evaluated in 3T3-L1 preadipocyte cells. Compds. I, II, and III were found to possess strong insulin-sensitizing activity in vitro and were selected for further hypoglycemic evaluation in vivo.
IT **610280-91-6P 610280-92-7P 610280-94-9P**
610280-96-1P 610280-97-2P 610280-99-4P
610281-01-1P 610281-03-3P 610281-05-5P
610281-07-7P 610281-08-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and insulin-sensitizing activity of a series of 2-benzyl-1,3-dicarbonyl derivs.)
RN 610280-91-6 CA
CN Propanediamide, N,N'-dihydroxy-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 610280-92-7 CA
CN Propanedioic acid, [[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, dihydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 610280-94-9 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(2-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 610280-96-1 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(3-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 610280-97-2 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(4-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 610280-99-4 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(2-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)



RN 610281-01-1 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(3-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610281-03-3 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(4-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610281-05-5 CA
CN Propanediamide, N,N'-dimethyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 610281-07-7 CA
CN Propanediamide, 2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-N,N'-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

RN 610281-08-8 CA
CN Propanediamide, N,N'-dicyclopropyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/713,722

```
=> d his

     (FILE 'HOME' ENTERED AT 14:18:31 ON 26 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 14:18:38 ON 26 MAY 2005
L1               STRUCTURE UPLOADED
L2             0 S L1 SAM
L3            31 S L1 FULL

     FILE 'CA' ENTERED AT 14:19:48 ON 26 MAY 2005
L4             5 S L3

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:20:30 ON 26 MAY 2005
```